Alopecia areata (AA) is a dermatological disease characterized by non-scarring hair loss of the scalp and/or body, with an unpredictable and variable evolution in the patients in which, despite multidisciplinary efforts, its etiology is not entirely known, although some evidence suggests that environmental, immunological and genetic factors could be generating the disease. The aim of this review is to provide an updated panorama of the clinical characteristics, diagnosis and treatment of AA, to analyze the mechanisms that could participate in its etiology, as well as to review some of the most important genetic variants that could confer susceptibility to the development of this disease.
INTRODUCTION
Alopecia is a common finding, although in some cases it can be associated with other diseases. 1, 2 One example is alopecia areata (AA) (OMIM 104000), which is c h a r a c t e r i z e d b y n o n -s c a r r i n g hair loss. 3 It has a variable and unpredictable evolution in each patient 4 and is classified into the following three groups according to severity and the areas where hair loss is observed: 1) alopecia areata in patches (AA), considered the most common form and identified by round or oval patches on the head (90% of cases) or in different parts of the body; 2) alopecia totalis (AT), in which there is a complete or almost complete absence of hair on the scalp; and 3) alopecia universalis (AU), established as the most severe and differentiated from the previous two because the total loss of hair is observed all over the body in addition to the face and scalp.
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Epidemiology
Diverse studies have established that AA affects 1-2% of the general population with an estimated lifetime risk of 1.7%. 7, 8 However, prevalence can vary between 0.1 and 6.9% depending on the population studied. 9 In the United States, AA affects 0.7 to 3% of its population. In the United Kingdom, approximately 2% of the population presents this disease. 10 In Mexico, the reported prevalence is between 0.2 to 3.8% 11 ; in Korea, it has been estimated that AA affects between 0.9 and 6.9% of individuals. 12 AA does not distinguish genders, although some reports suggest a slight predominance in women. 3, 13 However, this can depend on the population studied, since in countries like India and Turkey, the majority of cases correspond to men 14 with these presenting the most severe forms in comparison to women (63% vs. 36% respectively). 15 On the other hand, it has been established that AA affects all age groups 16 , although approximately 25% of the individuals are children. 17 AA in neonates occurs less frequently and according to the literature, the condition may appear in the first months of life. 18, 19 The age range in which AA is presented, is between 4-5 years and 15-40 years of age, with a higher prevalence between 10 and 25 years (60%). Nevertheless, recent studies report that 1-2% of individuals younger than 2 years and 21-24% under 16 years, are affected. AA rarely occurs in adults greater than 60 years. 9, 13, 20 
Etiology
The basic structure of the hair f o l l i c l e i s c o n s i d e r e d t h e m o s t complicated and important annexes Review of the skin. Its functions include protecting the skin from ultraviolet radiation, suppression of heat loss, and touch sensation. 3 The follicle passes through three phases during a normal growth cycle: anagen, catagen and telogen. The anagen phase is considered the growth phase (approximately 1 cm per month) and thus it is the longest (2-6 years). 7 In the catagen phase (2-4 weeks), hair growth is interrupted, i.e., a process of keratinocyte apoptosis occurs; in addition, there is preparation for the last phase of the cycle. 3 The telogen phase (2-3 months) is characterized by a stage of inactivity in which the hair is gradually lost before beginning a new growth cycle. 21 However, in patients with AA, hair loss could be due to an alteration of one of these follicle growth phases, in other words, a premature transition from the anagen to the catagen 2 or the anagen to telogen phase could happen.
7. Since this event cannot occur alone, several reports have suggested that despite the fact that the etiology of AA is not well known, it is possible that environmental, immunologic and genetic factors are responsible for its development.
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Environmental factors
With regard to the environment, has been proposed that stress could be one of the factors that could contribute to the development of AA.
Studies have reported that at least 23% of patients have had an emotional event or an identity crisis before the onset of AA. 11, 24, 25 Other factors such as infections, toxins and even food, could be associated with immune dysregulation processes and thus have been proposed as possible triggers of the disease, although not all have been validated.
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Immunological factors
Several research groups have reported that AA has a strong association with autoimmune diseases such as vitiligo. It has been estimated that a patient with AA has a two times greater probability of having vitiligo than the general population. Patients with AT and AU also have a higher risk, while individuals who already have vitiligo have a four times greater risk of developing AA. 26 It has been observed that 2.3% of patients with thyroid disease, 3.2% of patients with type 1 diabetes mellitus, 0.9% with rheumatoid arthritis, 10-60% with pernicious anemia and 4.1% of patients with vitiligo, may develop AA, 14,27 although Addison's disease, systemic lupus erythematosus, myasthenia gravis, scleroderma, allergic rhinitis, atopic dermatitis, asthma 24 and psoriasis, 28 have also been associated, therefore, a positive history of autoimmune diseases, could represent a group of patients with AA. 10 In addition to this, it has been hypothesized that AA is caused because patients develop antibodies that affect the structure of their own hair follicles in the anagen phase, specifically, CD4+ and CD8+ T lymphocytes infiltrate the bulb of the hair follicle. 13, 29 CD8+ lymphocytes are mainly responsible for follicular damage and predominate during activation of the disease, while CD4+ lymphocytes are fewer and only contribute together with CD8+ cells in the development of AA. Although It has been proposed that not only CD4+ and CD8+ lymphocytes are involved in these processes but also, natural killer cells, macrophages, Langerhans cells, and cytokines, 30, 31 which could be generating three events: 1) an inflammatory process at the periphery of the patches, 2) an alteration of the hair follicle cycles, and 3) growth inhibition. 29 
Genetic factors
Most cases of AA are sporadic. 32 However, there are reports that mention a strong association between genetics factors and development of the disease, 9 supported by three types of Figure 1 . Phases of hair follicle growth.
Normal growth cycle of hair follicle and one of the alterations that could occur during the phases in individuals with AA.
e406 / Arch Argent Pediatr 2017;115(6):e404-e411 / Review studies: 1) family-based linkage, 2) studies in monozygotic twins, in which a concordance of 50% of developing the disease has been observed, 14 and 3) studies based on heritability in first-degree relatives, 10 in which a positive family incidence of 10 to 42% for AA has been reported. 16 Three percent of patients have at least one brother with the disease and 2% have at least one affected child, 10 with an estimated risk of 6%, in children of patients with AA. 13 On the other hand, it has been found that AA has a polygenic origin, in other words, it does not follow a common Mendelian pattern that can be attributed to a single gene locus; therefore, multiple genes intervene causing a greater susceptibility to developing the disease. 9 For this reason, in recent years, association studies of candidate genes for AA have been developed 27 and these genes have been mostly selected according to the following characteristics: 1) they participate in inflammatory processes, 2) they are immune-regulatory genes, and 3) they regulate the differentiation and maintain T cells. 24 
Clinical manifestations
Patchy AA is the most common form in children. It is characterized by the presence of circular or oval areas of non-scarring hair loss, on the scalp, eyebrows, eyelashes or any other place where there is hair. 20 In adults, in addition to the mentioned areas, patches can also be observed in the beard or in the pubic area and the size and number can be variable in each patient. 21 In more severe cases such as AT or AU, the almost complete loss of hair on the scalp or face and the entire body are respectively evident. 
Diagnosis
Obtaining an accurate diagnosis in patients with AA can be at times complex, particularly in newborns given the little hair they have at this stage. 1, 20 For this reason, the diagnosis should be based on clinical history and physical examination. 34 The clinical history is one of the key elements to identify possible triggers of the disease or provides evidence to determine the presence of another clinical disorder. 2 The physical examination will allow to establish an accurate diagnosis, with the support of techniques like the hair pull test and the Jacquet's sign. Also, using dermatoscopy, small yellow spots and exclamation point hairs -short, broken off, distally wide hairs approximately 3 to 4 mm long-can be seen at the periphery of the patch, although this characteristic is only seen in cases of simple AA. 2, 21, 35 The nails and appearance of the hair should be considered during physical examination. It has been reported that 10 to 66% of patients with AA present pitting ungueal among the most common, 2,10,25 while white, thin, shine-less hair can be seen in some patients.
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Histological examination although are not necessarily essential for the diagnosis of AA, could be useful in particular cases, since they allow the observation of cell aggregates around the hair bulb, which are responsible for the inflammatory processes. 54 On the other hand, laboratory tests are indicated in those cases where associated autoimmune conditions exist.
The differential diagnosis should also be considered to establish a precise diagnosis in patients with AA. In children, it is mainly performed with trichotillomania and tinea capitis, congenital triangular alopecia and transient neonatal hair loss 20 and in both in children and adults, telogen effluvium and traction alopecia should be considered. Lupus erythematosus and androgenic alopecia are of greater interest in adults.
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Treatment
AA is not easily treated, and unfortunately, no universal totally accepted treatment exists for all cases. However, British and Japanese treatment guidelines for AA have suggested topical immunotherapy (dinitrochlorobenzene, diphenylcyclopropenone o el squaric acid dibutylester) as one of the most effective options, 7, 8 although intralesional, topical or systemic corticosteroids (fluocinolone acetonide, triamcinolone acetonide, dexamethasone, clobetasol propionate and methylprednisolone), are used in patients with AA. 10, 14 Other treatment options include anthralin, azathioprine, 10 cyclosporine, methotrexate, sulfasalazine, minoxidil, 21 adalimumab, 29 tofacitinib and ruxolitinib. 57, 58 All of which are oriented towards eliminating inflammation, preventing hair loss, and controlling symptoms.
2.
It is important to point out that patients under treatment with these drugs should be constantly clinically monitored due to the adverse effects that can be generated such as weight gain, avascular necrosis, hypertension, diabetes, sleep disturbances, mood changes, acne, sensitivity to allergies 21 , atypical hair coloration 59 or even diseases such as vitiligo, which can be caused by diphenylcyclopropenone. 26 Despite the different treatment options for AA, it is clear that each individual responds differently to the drug and the disease; 29 examples of this are cases of severe AA, in which the response to any drug could depend on a set of factors, such as age at start of onset, patient age, family history, in addition to the clinical conditions that could be associated. 24 In children, treatment options are very limited given the adverse effects generated. Therefore, drugs with minor adverse effects should be prescribed, considering that the majority of the cases in this age group are of spontaneous remission. 60 For patchy AA cases, topical corticosteroids such as 0.05% betamethasone dipropionate, 0.05% clobetasol propionate, or 0.1% triamcinolone acetonide, may be used for 3 to 4 months. Intralesional corticosteroids in children are not tolerated and should be avoided. 25, 61 However, both 5% minoxidil and 1-2% topical antraline could be prescribed in these patients. 62 In severe cases of AA, topical immunotherapy (diphenylcyclopropenone), has been used. Although corticosteroid pulse therapy has shown lower adverse effects at low doses. 63, 64 Methotrexate is being evaluated in children with AT or AU and prednisolone has been recommended in some cases.
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Prognosis
The course of AA in both children and adults is unpredictable. However, it has been established that a poor prognosis could be due to the early age of onset, the extent of hair loss, nail abnormalities, a positive family history for AA and comorbidity with autoimmune diseases. 21 Severe cases occur more frequently before puberty and have less than a 10% chance of regaining hair despite treatments. 63 
Psychological management
Hair loss in children and adults has important psychological effects not only in affected patients but also in families given the cosmetic effect it causes. Low self-esteem, anxiety, depression and negative effects on their quality of life, are some examples. 57, 66 In children, such effects could impact on their growth and development. 20, 64 Therefore, the patient with AA should receive both medical and psychological counseling. The Physician should explain to the patient or patient's parents (when they are children), the unpredictable nature of the condition, the possible course, the treatments available and the success or failure that these may have. Mental health specialists must work with the patient in managing emotions and providing emotional support in cases of relapse.
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CONCLUSION
AA is an increasingly common disease in individuals, which has significant emotional effects in children and adults. At present, there are no universal treatments that guarantee low rates of relapse and minor adverse effects. Therefore, it is necessary that new drugs be developed, from genes (therapeutic targets) that participate in autoimmune or inflammatory processes and in the development or function of the hair follicle. n
